Highlights AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
2.42 ^USD	-2.02%		-5.47%	-88.19%

04-03	North American Morning Briefing : Powell Awaited -2-	DJ
04-02	JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stocks Seen -2-	04-02	DJ
AN2 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
AN2 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
North American Morning Briefing : Stocks Seen -2-	02-13	DJ
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Monday As Traders Focus on Inflation, Sales Data	02-12	MT
AN2 Therapeutics to pause lung disease study enrollment	02-12	RE
AN2 Therapeutics, Inc. Announces to Voluntary Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex Lung Disease	02-12	CI
AN2 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
AN2 Therapeutics Receives Grant from Gates Foundation to Discover Tuberculosis, Malaria Treatments	26/09/23	MT
AN2 Therapeutics, Inc. Commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex Lung Disease	13/09/23	CI
AN2 Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
AN2 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
AN2 Therapeutics, Inc. Enrolls its Phase 2/3 Pivotal Trial	11/05/23	CI
AN2 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	29/03/23	AQ
AN2 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	09/11/22	AQ
AN2 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/11/22	CI
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease	06/10/22	CI
AN2 Therapeutics Wins Contract Valued Up to $17.8 Million From US National Institute of Allergy and Infectious Diseases	29/09/22	MT
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million	29/09/22	CI
AN2 Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Business Updates - Form 8-K	11/08/22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Highlights

Filters